New drugs for diabetes types I & II
Ninety to Ninety-five percent of diabetics are type 2. We have more children under the age of 18 with type 2 diabetes than ever before in history. What’s the big deal? Diabetes is a disease that affects every organ in the body. Many people walk around with this disease and are not even aware. The lack of knowledge about diabetes unnecessarily leads to complications for many.
For the original version including any supplementary images or video, visit http://www.travis.af.mil/news/story.asp?id=123370188
Three have been recently approved by the FDA and three more are promising drugs awaiting FDA approval. Five of the new drugs are for diabetes type II and the remaining drug addresses type I diabetes Japanese pharmaceutical company Takeda Pharmaceutical CL and its American sister company Takeda Pharmaceuticals U.S.A. Inc. recently received approval for three new types II diabetes drugs: Nesina (alogliptin), Oseni (alogliptin and pioglitazone) and Kazano (alogliptin and metformin HCI). Research is backed by world-wide clinical trials with over 13,000 participants. SEE RELATED: Hepatitis C will be eradicated starting in weeks Nesina (alogliptin) works by increasing the active incretins enabling the pancreas to secrete insulin in a glucose dependent manner.
For the original version including any supplementary images or video, visit http://communities.washingtontimes.com/neighborhood/steps-authentic-happiness-positive-psychology/2013/nov/7/new-drugs-diabetes-types-i-ii/